Viking Therapeutics, Inc. (VKTX)
34.00
+0.50
(+1.48%)
USD |
NASDAQ |
Sep 03, 16:00
34.00
0.00 (0.00%)
After-Hours: 16:36
Viking Therapeutics Research and Development Expense (Annual) : 344.96M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 344.96M |
| December 31, 2024 | 101.64M |
| December 31, 2023 | 63.81M |
| December 31, 2022 | 54.23M |
| December 31, 2021 | 44.98M |
| December 31, 2020 | 31.93M |
| December 31, 2019 | 23.56M |
| Date | Value |
|---|---|
| December 31, 2018 | 19.04M |
| December 31, 2017 | 13.74M |
| December 31, 2016 | 9.000M |
| December 31, 2015 | 6.967M |
| December 31, 2014 | 22.22M |
| December 31, 2013 | 0.0116M |
| December 31, 2012 | 0.0689M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Eli Lilly & Co. | 13.34B |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Skye Bioscience, Inc. | 41.64M |
| Eledon Pharmaceuticals, Inc. | 66.27M |